The Jacaranda FM News team is based in Gauteng – but covers local and international news of the day, providing the latest developments online and on-air. News bulletins run from 5am to 7pm weekdays, and from 7am to 6pm on weekends and public holidays. Tune into Jacaranda FM, or log on to www.jacarandafm.com, for the news you need to know.. now.
…
continue reading
Content provided by Clarivate. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clarivate or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Lighting the touch paper for next generation nucleic acid therapies
MP3•Episode home
Manage episode 362352820 series 2813433
Content provided by Clarivate. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clarivate or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode Mike Ward, Clarivate’s Head of Thought Leadership for Life sciences and healthcare, spoke to Johnny Ohlson, Founder of Touchlight, a company who has developed a novel synthetic DNA vector. In recent years, we've seen that by harnessing the power of DNA, it has been possible to achieve success in treating previously incurable hereditary diseases and even tackle major pandemics. However, whether the answer is cell or gene therapies or RNA vaccines, one thing they all have in common is that they require DNA in some form or another as the starting material. Through Touchlight, Johnny Ohlson and his talented team have built a business that can make DNA at unprecedented speed, scale and purity. Johnny, a serial entrepreneur not originally from a biopharma background, shares with us his story of breaking successfully into a complex industry. This podcast demonstrates that innovation at its heart is more about a combination of vision, relationships and talented people rather than prior experience.
…
continue reading
Hosted on Acast. See acast.com/privacy for more information.
48 episodes
MP3•Episode home
Manage episode 362352820 series 2813433
Content provided by Clarivate. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clarivate or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode Mike Ward, Clarivate’s Head of Thought Leadership for Life sciences and healthcare, spoke to Johnny Ohlson, Founder of Touchlight, a company who has developed a novel synthetic DNA vector. In recent years, we've seen that by harnessing the power of DNA, it has been possible to achieve success in treating previously incurable hereditary diseases and even tackle major pandemics. However, whether the answer is cell or gene therapies or RNA vaccines, one thing they all have in common is that they require DNA in some form or another as the starting material. Through Touchlight, Johnny Ohlson and his talented team have built a business that can make DNA at unprecedented speed, scale and purity. Johnny, a serial entrepreneur not originally from a biopharma background, shares with us his story of breaking successfully into a complex industry. This podcast demonstrates that innovation at its heart is more about a combination of vision, relationships and talented people rather than prior experience.
…
continue reading
Hosted on Acast. See acast.com/privacy for more information.
48 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.